HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 20.00M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 133.96M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 1.37B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $20.00M | $133.96M | (m) | (m) | $1.37B | (m) |
| 2026-03-31 | (m) | (m) | $20.00M | $138.81M | (m) | (m) | $1.27B | (m) |
| 2025-12-31 | (m) | (m) | $20.00M | $143.66M | (m) | (m) | $1.27B | (m) |
| 2025-09-30 | (m) | (m) | $20.00M | $148.51M | (m) | (m) | $1.21B | (m) |
| 2025-06-30 | (m) | (m) | $18.75M | $153.34M | (m) | (m) | $1.11B | (m) |
| 2025-03-31 | (m) | (m) | $17.50M | $158.18M | (m) | (m) | $1.06B | (m) |
| 2024-12-31 | (m) | (m) | $16.25M | $163.02M | (m) | (m) | $999.20M | (m) |
| 2024-09-30 | (m) | (m) | $15.00M | $167.85M | (m) | (m) | $928.13M | (m) |
| 2024-06-30 | (m) | (m) | $15.00M | $171.42M | (m) | (m) | $858.38M | (m) |
| 2024-03-31 | (m) | (m) | $15.00M | $175.00M | (m) | (m) | $846.99M | (m) |
| 2023-12-31 | (m) | (m) | $15.00M | $178.57M | (m) | (m) | $811.45M | (m) |
| 2023-09-30 | (m) | (m) | $15.00M | $182.13M | (m) | (m) | $777.77M | (m) |
| 2023-06-30 | (m) | (m) | $11.00M | $180.49M | (m) | (m) | $760.18M | (m) |
| 2023-03-31 | (m) | (m) | $6.50M | $185.06M | (m) | (m) | $715.09M | (m) |
| 2022-12-31 | (m) | (m) | $2.00M | $189.65M | (m) | (m) | $673.87M | (m) |
| 2022-09-30 | (m) | (m) | $2.00M | $189.72M | (m) | (m) | $643.46M | (m) |
| 2022-06-30 | (m) | (m) | $2.00M | $189.81M | (m) | (m) | $505.03M | (m) |
| 2022-03-31 | (m) | (m) | $2.00M | $189.90M | (m) | (m) | $464.00M | (m) |
| 2021-12-31 | (m) | (m) | $2.00M | $189.98M | (m) | (m) | $433.44M | (m) |
| 2021-09-30 | (m) | (m) | $2.00M | $190.07M | (m) | (m) | $391.09M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $195.61M | (m) | (m) | $359.69M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $194.91M | (m) | (m) | $337.25M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $194.25M | (m) | (m) | $427.07M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $192.86M | (m) | (m) | $320.07M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $97.95M | (m) | (m) | $106.70M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |